Study Evaluating Cyclosporine Dose Reduction and Cyclosporine Elimination in Chinese Kidney Transplants

NCT00257387

Last updated date
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Kidney Transplant
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects with end-stage renal disease scheduled to receive a primary renal allograft from a cadaveric donor, from a living-unrelated donor, or a living-related HLA-mismatched donor.

- Subjects must be at least 18 years of age.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Subjects with active major infection, including active hepatitis B or C infection,
HIV, decreased platelets, elevated lipids, or multiple organ transplants.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Kidney TransplantA Study Of CP-690,550 In Stable Kidney Transplant Patients
NCT01710033
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Los Angeles, California
  5. Indianapolis, Indiana
  6. Minneapolis, Minnesota
  7. St Louis, Missouri
  8. St. Louis, Missouri
  9. Livingston, New Jersey
  10. Madison, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Kidney TransplantStudy Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant Recipients
NCT00137345
  1. San Diego, California
  2. San Francisco, California
  3. Denver, Colorado
  4. New Haven, Connecticut
  5. Gainesville, Florida
  6. Tampa, Florida
  7. Atlanta, Georgia
  8. Chicago, Illinois
  9. Portland, Maine
  10. Springfield, Massachusetts
  11. Detroit, Michigan
  12. New York, New York
  13. Charlotte, North Carolina
  14. Durham, North Carolina
  15. Cleveland, Ohio
  16. Cleveland, Ohio
  17. Toledo, Ohio
  18. Philadelphia, Pennsylvania
  19. Philadelphia, Pennsylvania
  20. Providence, Rhode Island
  21. Charleston, South Carolina
  22. Dallas, Texas
  23. Houston, Texas
  24. Buenos Aires, Capital Ferderal
  25. Buenos Aires, Capital Ferderal
  26. Buenos Aires, Capital Ferderal
  27. Buenos Aires, Capital Ferderal
  28. Buenos Aires, Capital Ferderal
  29. Buenos Aires,
  30. Ciudad de Bs As,
  31. Cordoba,
  32. Cordoba,
  33. Camperdown,
  34. Parkville,
  35. Randwick,
  36. Westmead,
  37. Woodville South,
  38. Woolloongabba,
  39. Wien,
  40. London, Ontario
  41. Cote du Palais, Quebec
  42. Montreal, Quebec
  43. Puente Alto,
  44. Santiago,
  45. Talca,
  46. Vina del Mar,
  47. Nicosia,
  48. Montpellier Cedex,
  49. Paris Cedex 15,
  50. Munster,
  51. Athens,
  52. Thessaloniki,
  53. Budapest,
  54. Debrecen,
  55. Pecs,
  56. Szeged,
  57. Bari,
  58. Cagliari,
  59. Torino,
  60. Oslo,
  61. Carnaxide-lisboa,
  62. Coimbra,
  63. Lisboa,
  64. Singapore,
  65. Cape Town,
  66. Cape Town,
  67. Johannesburg,
  68. Barcelona,
  69. La Coruã'a,
  70. La Laguna / Santa Cruz de Tenerife,
  71. Madrid,
  72. Madrid,
  73. Santander,
  74. Valencia,
  75. Uppsala,
  76. Taipei,
  77. Antalya,
  78. Istanbul,
  79. Izmir,
  80. Glasgow,
  81. Leicester,
  82. Manchester,
ALL GENDERS
13 Years+
years
MULTIPLE SITES
Kidney TransplantStudy Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus
NCT00502242
  1. Los Angeles, California
  2. Los Angeles, California
  3. San Francisco, California
  4. Aurora, Colorado
  5. Denver, Colorado
  6. Gainesville, Florida
  7. Chicago, Illinois
  8. Iowa City, Iowa
  9. Lexington, Kentucky
  10. Portland, Maine
  11. Boston, Massachusetts
  12. Springfield, Massachusetts
  13. Springfield, Massachusetts
  14. Gosse Pointe, Michigan
  15. Buffalo, New York
  16. Valhalla, New York
  17. Cleveland, Ohio
  18. Cleveland, Ohio
  19. Harrisburg, Pennsylvania
  20. Philadelphia, Pennsylvania
  21. Philadelphia, Pennsylvania
  22. Philadelphia, Pennsylvania
  23. Providence, Rhode Island
  24. Charleston, South Carolina
  25. Capital Federal, Buenos Aires
  26. San Martin, Buenos Aires
  27. Buenos Aires,
  28. Cordoba,
  29. Córdoba,
  30. Brisbane, Queensland
  31. North Terrace,
  32. Woodville South,
  33. Linz,
  34. Rio de Janeiro, RJ
  35. Porto Alegre, RS
  36. Porto Alegre, RS
  37. Sao Paulo, SP
  38. Sao Paulo, SP
  39. Sao Paulo, SP
  40. Sao Paulo, SP
  41. Montreal, Quebec
  42. Erlangen,
  43. Szeged,
  44. Petach Tikva,
  45. Mexico City,
  46. Veracruz,
  47. Szczecin,
  48. Johannesburg, Gauteng
  49. Cape Town, Western Cape
  50. Cape Town, Western Cape
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Evaluating Cyclosporine Dose Reduction and Cyclosporine Elimination in Chinese Kidney Transplants
Official Title  ICMJE A Nonrandomized, Open-label, Multicenter, Sequential Phase Study to Evaluate the Safety and Efficacy of Cyclosporine Dose Reduction and Cyclosporine Elimination in Chinese De Novo Renal Allograft Recipients Receiving Rapamune
Brief Summary Evaluate the incidence of acute rejection at 12 months after transplantation in subjects receiving induction therapy with cyclosporine microemulsion (CsA) and Rapamune followed by CsA dose reduction (Phase I) with subjects receiving induction therapy with CsA and Rapamune followed by CsA discontinuation (Phase II) in Chinese de novo renal allograft recipients.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Condition  ICMJE Kidney Transplant
Intervention  ICMJE Drug: Cyclosporine
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: November 21, 2005)
120
Original Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE August 2006
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subjects with end-stage renal disease scheduled to receive a primary renal allograft from a cadaveric donor, from a living-unrelated donor, or a living-related HLA-mismatched donor.
  • Subjects must be at least 18 years of age.

Exclusion Criteria:

  • Subjects with active major infection, including active hepatitis B or C infection, HIV, decreased platelets, elevated lipids, or multiple organ transplants.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00257387
Other Study ID Numbers  ICMJE 0468H1-101308
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Medical Monitor, MDWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date June 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP